Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 106 articles:
HTML format
Text format



Single Articles


    August 2019
  1. CESPEDES FELICIANO EM, Chen WY, Bradshaw PT, Prado CM, et al
    Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors.
    J Clin Oncol. 2019 Aug 1:JCO1900286. doi: 10.1200/JCO.19.00286.
    PubMed     Text format     Abstract available


    July 2019
  2. MUSS HB, Polley MC, Berry DA, Liu H, et al
    Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
    J Clin Oncol. 2019 Jul 24:JCO1900647. doi: 10.1200/JCO.19.00647.
    PubMed     Text format     Abstract available


  3. ROSS M, Geyer CE Jr
    Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?
    J Clin Oncol. 2019 Jul 15:JCO1900877. doi: 10.1200/JCO.19.00877.
    PubMed     Text format    


  4. MOSKOWITZ CS, Chou JF, Neglia JP, Partridge AH, et al
    Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1802219. doi: 10.1200/JCO.18.02219.
    PubMed     Text format     Abstract available


  5. OEFFINGER KC, Ford JS, Moskowitz CS, Chou JF, et al
    Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1900547. doi: 10.1200/JCO.19.00547.
    PubMed     Text format     Abstract available


    June 2019
  6. HINDIE E, Groheux D
    Interim [(18)F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 28:JCO1900776. doi: 10.1200/JCO.19.00776.
    PubMed     Text format    


  7. RAJAGOPAL PS, Catenacci DVT, Olopade OI
    The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now.
    J Clin Oncol. 2019 Jun 27:JCO1900160. doi: 10.1200/JCO.19.00160.
    PubMed     Text format    


  8. TAYLOR A, Tischkowitz M
    Caveat Emptor: The Perils of Panel Testing in Hereditary Breast Cancer.
    J Clin Oncol. 2019 Jun 27:JCO1900122. doi: 10.1200/JCO.19.00122.
    PubMed     Text format    


  9. COPUR MS, Jonglertham P, Zusag T
    Should All Patients With a Diagnosis of Breast Cancer Undergo Expanded Panel Testing?
    J Clin Oncol. 2019 Jun 27:JCO1900064. doi: 10.1200/JCO.19.00064.
    PubMed     Text format    


  10. GOETZ MP, Suman VJ, Nakamura Y, Kiyotani K, et al
    Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.
    J Clin Oncol. 2019 Jun 18:JCO1900504. doi: 10.1200/JCO.19.00504.
    PubMed     Text format    


  11. HENRY NL, Somerfield MR, Abramson VG, Ismaila N, et al
    Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    J Clin Oncol. 2019 Jun 17:JCO1900948. doi: 10.1200/JCO.19.00948.
    PubMed     Text format     Abstract available


  12. KANTOR ED, Romano ME
    Phthalate Exposure From Prescription Medications and Breast Cancer Risk.
    J Clin Oncol. 2019 Jun 7:JCO1901003. doi: 10.1200/JCO.19.01003.
    PubMed     Text format    


  13. CONFORTI F, Pala L
    Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
    J Clin Oncol. 2019 Jun 7:JCO1900559. doi: 10.1200/JCO.19.00559.
    PubMed     Text format    


  14. HURVITZ SA, Martin M, Jung KH, Huang CS, et al
    Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
    J Clin Oncol. 2019 Jun 3:JCO1900882. doi: 10.1200/JCO.19.00882.
    PubMed     Text format     Abstract available


  15. WOLFF AC, Tung NM, Carey LA
    Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 3:JCO1901159. doi: 10.1200/JCO.19.01159.
    PubMed     Text format    


    May 2019
  16. ANDRE F, Ismaila N, Henry NL, Somerfield MR, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
    J Clin Oncol. 2019 May 31:JCO1900945. doi: 10.1200/JCO.19.00945.
    PubMed     Text format     Abstract available


  17. FABIAN CJ
    Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction?
    J Clin Oncol. 2019 May 13:JCO1900656. doi: 10.1200/JCO.19.00656.
    PubMed     Text format    


  18. UNTCH M, Jackisch C, Schneeweiss A, Schmatloch S, et al
    NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
    J Clin Oncol. 2019 May 13:JCO1801842. doi: 10.1200/JCO.18.01842.
    PubMed     Text format     Abstract available


  19. EHRHARDT MJ, Howell CR, Hale K, Baassiri MJ, et al
    Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).
    J Clin Oncol. 2019 May 10:JCO1801099. doi: 10.1200/JCO.18.01099.
    PubMed     Text format     Abstract available


  20. KUEMMEL S, Holtschmidt J, Gerber B, Von der Assen A, et al
    Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial.
    J Clin Oncol. 2019 May 1:JCO1802092. doi: 10.1200/JCO.18.02092.
    PubMed     Text format     Abstract available


    April 2019
  21. YU KD, Shao ZM
    Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up.
    J Clin Oncol. 2019 Apr 29:JCO1802468. doi: 10.1200/JCO.18.02468.
    PubMed     Text format    


  22. AHERN TP, Broe A, Lash TL, Cronin-Fenton DP, et al
    Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study.
    J Clin Oncol. 2019 Apr 17:JCO1802202. doi: 10.1200/JCO.18.02202.
    PubMed     Text format     Abstract available


  23. KURIAN AW, Ward KC, Howlader N, Deapen D, et al
    Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854.
    PubMed     Text format     Abstract available


  24. FOLDI J, O'Meara T, Marczyk M, Sanft T, et al
    Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
    J Clin Oncol. 2019 Apr 3:JCO1801933. doi: 10.1200/JCO.18.01933.
    PubMed     Text format    


  25. TOLANEY SM, Guo H, Pernas S, Barry WT, et al
    Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Apr 2:JCO1900066. doi: 10.1200/JCO.19.00066.
    PubMed     Text format     Abstract available


    March 2019
  26. CHANDARLAPATY S, Razavi P
    Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.
    J Clin Oncol. 2019 Mar 28:JCO1900090. doi: 10.1200/JCO.19.00090.
    PubMed     Text format    


  27. FREEDMAN RA, Gelman RS, Anders CK, Melisko ME, et al
    TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    J Clin Oncol. 2019 Mar 12:JCO1801511. doi: 10.1200/JCO.18.01511.
    PubMed     Text format     Abstract available


    February 2019
  28. REGAN MM, Fleming GF, Walley B, Francis PA, et al
    Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
    J Clin Oncol. 2019 Feb 27:JCO1802433. doi: 10.1200/JCO.18.02433.
    PubMed     Text format    


  29. TURNER NC, Liu Y, Zhu Z, Loi S, et al
    Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2019 Feb 26:JCO1800925. doi: 10.1200/JCO.18.00925.
    PubMed     Text format     Abstract available


  30. NITZ U, Gluz O, Clemens M, Malter W, et al
    West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
    J Clin Oncol. 2019 Feb 20:JCO1800028. doi: 10.1200/JCO.18.00028.
    PubMed     Text format     Abstract available


  31. ATEMA V, van Leeuwen M, Kieffer JM, Oldenburg HSA, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2019 Feb 14:JCO1800655. doi: 10.1200/JCO.18.00655.
    PubMed     Text format     Abstract available


  32. PAN K, Bosserman LD, Chlebowski RT
    Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    J Clin Oncol. 2019 Feb 11:JCO1801360. doi: 10.1200/JCO.18.01360.
    PubMed     Text format    


  33. DOWSETT M, Turner N
    Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.
    J Clin Oncol. 2019 Feb 11:JCO1801412. doi: 10.1200/JCO.18.01412.
    PubMed     Text format    


  34. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
    TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    J Clin Oncol. 2019 Feb 5:JCO2018787986. doi: 10.1200/JCO.2018.78.7986.
    PubMed     Text format     Abstract available


    January 2019
  35. HAMY AS, Tury S, Wang X, Gao J, et al
    Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    J Clin Oncol. 2019 Jan 31:JCO1800636. doi: 10.1200/JCO.18.00636.
    PubMed     Text format     Abstract available


  36. ARASU VA, Miglioretti DL, Sprague BL, Alsheik NH, et al
    Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
    J Clin Oncol. 2019 Jan 9:JCO1800378. doi: 10.1200/JCO.18.00378.
    PubMed     Text format     Abstract available


    December 2018
  37. DELLAPASQUA S, Gray KP, Munzone E, Rubino D, et al
    Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
    J Clin Oncol. 2018 Dec 27:JCO1800296. doi: 10.1200/JCO.18.00296.
    PubMed     Text format     Abstract available


  38. BEITSCH PD, Whitworth PW, Hughes K, Patel R, et al
    Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
    J Clin Oncol. 2018 Dec 7:JCO1801631. doi: 10.1200/JCO.18.01631.
    PubMed     Text format     Abstract available


  39. MILLIRON KJ, Griggs JJ
    Advances in Genetic Testing in Patients With Breast Cancer, High-Quality Decision Making, and Responsible Resource Allocation.
    J Clin Oncol. 2018 Dec 7:JCO1801952. doi: 10.1200/JCO.18.01952.
    PubMed     Text format    


  40. JOHNSTON S, Puhalla S, Wheatley D, Ring A, et al
    Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
    J Clin Oncol. 2018 Dec 6:JCO1801624. doi: 10.1200/JCO.18.01624.
    PubMed     Text format     Abstract available


    November 2018
  41. RUHSTALLER T, Giobbie-Hurder A, Colleoni M, Jensen MB, et al
    Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
    J Clin Oncol. 2018 Nov 26:JCO1800440. doi: 10.1200/JCO.18.00440.
    PubMed     Text format     Abstract available


  42. BURSTEIN HJ, Lacchetti C, Anderson H, Buchholz TA, et al
    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2018 Nov 19:JCO1801160. doi: 10.1200/JCO.18.01160.
    PubMed     Text format     Abstract available


    October 2018
  43. MANDELBLATT JS, Small BJ, Luta G, Hurria A, et al
    Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.
    J Clin Oncol. 2018 Oct 3:JCO1800140. doi: 10.1200/JCO.18.00140.
    PubMed     Text format     Abstract available


    September 2018
  44. CRUZ C, Llop-Guevara A, Garber JE, Arun BK, et al
    Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    J Clin Oncol. 2018 Sep 21:JCO2018786558. doi: 10.1200/JCO.2018.78.6558.
    PubMed     Text format     Abstract available


  45. BARDIA A, Parton M, Kummel S, Estevez LG, et al
    Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.
    J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392.
    PubMed     Text format     Abstract available


  46. SEIDMAN AD, Bordeleau L, Fehrenbacher L, Barlow WE, et al
    National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
    J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242.
    PubMed     Text format     Abstract available


  47. BEAU AB, Andersen PK, Vejborg I, Lynge E, et al
    Limitations in the Effect of Screening on Breast Cancer Mortality.
    J Clin Oncol. 2018 Sep 4:JCO2018780270. doi: 10.1200/JCO.2018.78.0270.
    PubMed     Text format     Abstract available


    August 2018
  48. GINSBURG O, Brennan P
    Genetic Testing for Breast Cancer in the Era of Multigene Panels: Can We Make an Impact on Population Health?
    J Clin Oncol. 2018 Aug 21:JCO2018793307. doi: 10.1200/JCO.2018.79.3307.
    PubMed     Text format    


  49. ZHENG Y, Walsh T, Gulsuner S, Casadei S, et al
    Inherited Breast Cancer in Nigerian Women.
    J Clin Oncol. 2018 Aug 21:JCO2018783977. doi: 10.1200/JCO.2018.78.3977.
    PubMed     Text format     Abstract available


  50. RIMAWI M, Ferrero JM, de la Haba-Rodriguez J, Poole C, et al
    First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase I
    J Clin Oncol. 2018 Aug 14:JCO2017767863. doi: 10.1200/JCO.2017.76.7863.
    PubMed     Text format     Abstract available


    July 2018
  51. PARKER PA, Peterson SK, Shen Y, Bedrosian I, et al
    Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.
    J Clin Oncol. 2018 Jul 25:JCO2018786442. doi: 10.1200/JCO.2018.78.6442.
    PubMed     Text format     Abstract available


  52. MILLER KD, O'Neill A, Gradishar W, Hobday TJ, et al
    Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
    J Clin Oncol. 2018 Jul 24:JCO2018792028. doi: 10.1200/JCO.2018.79.2028.
    PubMed     Text format     Abstract available


  53. HOUSTON TP, Ostroff JS
    Cardiovascular Risk Factors and Breast Cancer.
    J Clin Oncol. 2018 Jul 23:JCO1800041. doi: 10.1200/JCO.18.00041.
    PubMed     Text format    


  54. HU JJ, Urbanic JJ, Case LD, Takita C, et al
    Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population.
    J Clin Oncol. 2018 Jul 10:JCO2017771790. doi: 10.1200/JCO.2017.77.1790.
    PubMed     Text format     Abstract available


    June 2018
  55. RAMAKRISHNA N, Temin S, Chandarlapaty S, Crews JR, et al
    Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
    J Clin Oncol. 2018 Jun 25:JCO2018792713. doi: 10.1200/JCO.2018.79.2713.
    PubMed     Text format     Abstract available


  56. GIORDANO SH, Temin S, Chandarlapaty S, Crews JR, et al
    Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
    J Clin Oncol. 2018 Jun 25:JCO2018792697. doi: 10.1200/JCO.2018.79.2697.
    PubMed     Text format     Abstract available


  57. LYMAN GH, Greenlee H, Bohlke K, Bao T, et al
    Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
    J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721.
    PubMed     Text format     Abstract available


  58. SLAMON DJ, Neven P, Chia S, Fasching PA, et al
    Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
    J Clin Oncol. 2018 Jun 3:JCO2018789909. doi: 10.1200/JCO.2018.78.9909.
    PubMed     Text format     Abstract available


    May 2018
  59. WOLFF AC, Hammond MEH, Allison KH, Harvey BE, et al
    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2018 May 30:JCO2018778738. doi: 10.1200/JCO.2018.77.8738.
    PubMed     Text format     Abstract available


  60. FASCHING PA, Loibl S, Hu C, Hart SN, et al
    BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
    J Clin Oncol. 2018 May 23:JCO2017772285. doi: 10.1200/JCO.2017.77.2285.
    PubMed     Text format     Abstract available


  61. TAYLOR C, McGale P, Bronnum D, Correa C, et al
    Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data.
    J Clin Oncol. 2018 May 23:JCO2017776351. doi: 10.1200/JCO.2017.77.6351.
    PubMed     Text format     Abstract available


  62. THAVENDIRANATHAN P, Abdel-Qadir H, Fischer HD, Liu Y, et al
    Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study.
    J Clin Oncol. 2018 May 23:JCO2018779736. doi: 10.1200/JCO.2018.77.9736.
    PubMed     Text format     Abstract available


  63. DENDULURI N, Chavez-MacGregor M, Telli ML, Eisen A, et al
    Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2018 May 22:JCO2018788604. doi: 10.1200/JCO.2018.78.8604.
    PubMed     Text format     Abstract available


  64. WANG L, Hong BY, Kennedy SA, Chang Y, et al
    Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies.
    J Clin Oncol. 2018 May 14:JCO2017773663. doi: 10.1200/JCO.2017.77.3663.
    PubMed     Text format     Abstract available


  65. LAMBERTINI M, Moore HCF, Leonard RCF, Loibl S, et al
    Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
    J Clin Oncol. 2018 May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858.
    PubMed     Text format     Abstract available


    April 2018
  66. SHERMAN KA, Przezdziecki A, Alcorso J, Kilby CJ, et al
    Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial.
    J Clin Oncol. 2018 Apr 24:JCO2017763318. doi: 10.1200/JCO.2017.76.3318.
    PubMed     Text format     Abstract available


  67. HAMOOD R, Hamood H, Merhasin I, Keinan-Boker L, et al
    Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
    J Clin Oncol. 2018 Apr 24:JCO2017763524. doi: 10.1200/JCO.2017.76.3524.
    PubMed     Text format     Abstract available


  68. DEGNIM AC, Winham SJ, Frank RD, Pankratz VS, et al
    Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.
    J Clin Oncol. 2018 Apr 20:JCO2017759480. doi: 10.1200/JCO.2017.75.9480.
    PubMed     Text format     Abstract available


  69. DOWSETT M, Sestak I, Regan MM, Dodson A, et al
    Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
    J Clin Oncol. 2018 Apr 20:JCO2017764258. doi: 10.1200/JCO.2017.76.4258.
    PubMed     Text format     Abstract available


  70. WHEELER SB, Spencer JC, Pinheiro LC, Carey LA, et al
    Financial Impact of Breast Cancer in Black Versus White Women.
    J Clin Oncol. 2018 Apr 18:JCO2017776310. doi: 10.1200/JCO.2017.77.6310.
    PubMed     Text format     Abstract available


  71. KORNBLUM N, Zhao F, Manola J, Klein P, et al
    Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of
    J Clin Oncol. 2018 Apr 17:JCO2017769331. doi: 10.1200/JCO.2017.76.9331.
    PubMed     Text format     Abstract available


  72. WANG SY, Dang W, Richman I, Mougalian SS, et al
    Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
    J Clin Oncol. 2018 Apr 16:JCO2017765941. doi: 10.1200/JCO.2017.76.5941.
    PubMed     Text format     Abstract available


  73. REINER AS, Sisti J, John EM, Lynch CF, et al
    Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
    J Clin Oncol. 2018 Apr 5:JCO2017773424. doi: 10.1200/JCO.2017.77.3424.
    PubMed     Text format     Abstract available


    March 2018
  74. HERSHMAN DL, Till C, Shen S, Wright JD, et al
    Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
    J Clin Oncol. 2018 Mar 27:JCO2017774414. doi: 10.1200/JCO.2017.77.4414.
    PubMed     Text format     Abstract available


  75. MASSARWEH SA, Sledge GW, Miller DP, McCullough D, et al
    Molecular Characterization and Mortality From Breast Cancer in Men.
    J Clin Oncol. 2018 Mar 27:JCO2017768861. doi: 10.1200/JCO.2017.76.8861.
    PubMed     Text format     Abstract available


  76. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
    Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
    J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
    PubMed     Text format     Abstract available


  77. UNTCH M, von Minckwitz G, Gerber B, Schem C, et al
    Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    J Clin Oncol. 2018 Mar 15:JCO2017759175. doi: 10.1200/JCO.2017.75.9175.
    PubMed     Text format     Abstract available


  78. KATZ SJ, Ward KC, Hamilton AS, Mcleod MC, et al
    Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
    J Clin Oncol. 2018 Mar 12:JCO2017762369. doi: 10.1200/JCO.2017.76.2369.
    PubMed     Text format     Abstract available


  79. WEDAM SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, et al
    US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
    J Clin Oncol. 2018 Mar 9:JCO2017746917. doi: 10.1200/JCO.2017.74.6917.
    PubMed     Text format     Abstract available


    February 2018
  80. WHARAM JF, Zhang F, Lu CY, Wagner AK, et al
    Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.
    J Clin Oncol. 2018 Feb 28:JCO2017752501. doi: 10.1200/JCO.2017.75.2501.
    PubMed     Text format     Abstract available


  81. ZARDAVAS D, Te Marvelde L, Milne RL, Fumagalli D, et al
    Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
    J Clin Oncol. 2018 Feb 22:JCO2017748301. doi: 10.1200/JCO.2017.74.8301.
    PubMed     Text format     Abstract available


  82. WAPNIR IL, Price KN, Anderson SJ, Robidoux A, et al
    Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
    J Clin Oncol. 2018 Feb 14:JCO2017765719. doi: 10.1200/JCO.2017.76.5719.
    PubMed     Text format     Abstract available


  83. KENNEDY L, Bhatta S, Hechmati G, Buchanan J, et al
    Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases.
    J Clin Oncol. 2018 Feb 1:JCO2017770115. doi: 10.1200/JCO.2017.77.0115.
    PubMed     Text format    


    January 2018
  84. NEUMAN HB, Schumacher JR, Francescatti AB, Adesoye T, et al
    Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
    J Clin Oncol. 2018 Jan 31:JCO2017755389. doi: 10.1200/JCO.2017.75.5389.
    PubMed     Text format     Abstract available


  85. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
    Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive E
    J Clin Oncol. 2018 Jan 26:JCO2017740126. doi: 10.1200/JCO.2017.74.0126.
    PubMed     Text format     Abstract available


  86. TRAINA TA, Miller K, Yardley DA, Eakle J, et al
    Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2016713495. doi: 10.1200/JCO.2016.71.3495.
    PubMed     Text format     Abstract available


  87. LAENKHOLM AV, Jensen MB, Eriksen JO, Rasmussen BB, et al
    PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017746586. doi: 10.1200/JCO.2017.74.6586.
    PubMed     Text format     Abstract available


  88. HAWLEY ST, Li Y, An LC, Resnicow K, et al
    Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
    J Clin Oncol. 2018 Jan 24:JCO2017748442. doi: 10.1200/JCO.2017.74.8442.
    PubMed     Text format     Abstract available


  89. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2018 Jan 22:JCO2017757526. doi: 10.1200/JCO.2017.75.7526.
    PubMed     Text format     Abstract available


  90. HOLOWATYJ AN, Cote ML, Ruterbusch JJ, Ghanem K, et al
    Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 17:JCO2017745448. doi: 10.1200/JCO.2017.74.5448.
    PubMed     Text format     Abstract available


  91. ZIVANOVIC BUJAK A, Dawson SJ
    Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 3:JCO2017765461. doi: 10.1200/JCO.2017.76.5461.
    PubMed     Text format    


  92. STOVER DG, Parsons HA, Ha G, Freeman SS, et al
    Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033.
    PubMed     Text format     Abstract available


    December 2017
  93. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Text format     Abstract available


  94. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
    J Clin Oncol. 2017 Dec 15:JCO2017747824. doi: 10.1200/JCO.2017.74.7824.
    PubMed     Text format     Abstract available


  95. BLUM JL, Robert N, Andersen J, Favret A, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
    J Clin Oncol. 2017 Dec 11:JCO2017753756. doi: 10.1200/JCO.2017.75.3756.
    PubMed     Text format    


    November 2017
  96. HENRY NL, Unger JM, Schott AF, Fehrenbacher L, et al
    Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
    J Clin Oncol. 2017 Nov 14:JCO2017746651. doi: 10.1200/JCO.2017.74.6651.
    PubMed     Text format     Abstract available


  97. HWONG AR, Mangurian C
    Improving Breast Cancer Screening and Care for Women With Severe Mental Illness.
    J Clin Oncol. 2017 Nov 2:JCO2017760462. doi: 10.1200/JCO.2017.76.0462.
    PubMed     Text format    


    October 2017
  98. GANZ PA, Romond EH, Cecchini RS, Rastogi P, et al
    Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Pacl
    J Clin Oncol. 2017 Oct 26:JCO2017741165. doi: 10.1200/JCO.2017.74.1165.
    PubMed     Text format     Abstract available


  99. JEMAL A, Robbins AS, Lin CC, Flanders WD, et al
    Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.
    J Clin Oncol. 2017 Oct 16:JCO2017737932. doi: 10.1200/JCO.2017.73.7932.
    PubMed     Text format     Abstract available


  100. VAN POZNAK C, Somerfield MR, Barlow WE, Biermann JS, et al
    Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
    J Clin Oncol. 2017 Oct 16:JCO2017754614. doi: 10.1200/JCO.2017.75.4614.
    PubMed     Text format     Abstract available


  101. SHAPIRO CL, Moriarty JP, Dusetzina S, Himelstein AL, et al
    Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    J Clin Oncol. 2017 Oct 12:JCO2017737437. doi: 10.1200/JCO.2017.73.7437.
    PubMed     Text format     Abstract available


  102. ASDOURIAN MS, Swaroop MN, Sayegh HE, Brunelle CL, et al
    Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
    J Clin Oncol. 2017 Oct 4:JCO2017737494. doi: 10.1200/JCO.2017.73.7494.
    PubMed     Text format     Abstract available


  103. GOETZ MP, Toi M, Campone M, Sohn J, et al
    MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    J Clin Oncol. 2017 Oct 2:JCO2017756155. doi: 10.1200/JCO.2017.75.6155.
    PubMed     Text format     Abstract available


    September 2017
  104. WU JW, Azoulay L, Majdan A, Boivin JF, et al
    Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
    J Clin Oncol. 2017 Sep 27:JCO2017734491. doi: 10.1200/JCO.2017.73.4491.
    PubMed     Text format     Abstract available


  105. IGLAY K, Santorelli ML, Hirshfield KM, Williams JM, et al
    Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients With Breast Cancer.
    J Clin Oncol. 2017 Sep 21:JCO2017734947. doi: 10.1200/JCO.2017.73.4947.
    PubMed     Text format     Abstract available


    February 2017
  106. LYMAN GH, Somerfield MR, Bosserman LD, Perkins CL, et al
    Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017;35:561-564.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: